PMID- 22008761
OWN - NLM
STAT- MEDLINE
DCOM- 20120210
LR  - 20211020
IS  - 1815-7920 (Electronic)
IS  - 1027-3719 (Print)
IS  - 1027-3719 (Linking)
VI  - 15
IP  - 11
DP  - 2011 Nov
TI  - Experience with rifabutin replacing rifampin in the treatment of tuberculosis.
PG  - 1485-9, i
LID - 10.5588/ijtld.11.0068 [doi]
AB  - SETTING: The use of a rifamycin in anti-tuberculosis treatment regimens is 
      crucial for shortening treatment and achieving favorable outcomes. Rifampin (RMP) 
      is the recommended rifamycin, although adverse effects (AEs) may require its 
      discontinuation. The use of rifabutin (RFB), a rifamycin with activity against 
      Mycobacterium tuberculosis, in patients with an RMP-related AE has not been well 
      studied. OBJECTIVE: To review our experience with RFB in tuberculosis (TB) 
      treatment. METHODS: We included TB patients who received RFB in their treatment 
      regimens from 2003 to 2009. We evaluated the indications for RFB and, if 
      applicable, the likelihood that RMP caused an AE. We identified RMPrelated AEs 
      associated with RFB intolerance. RESULTS: One hundred subjects were included. The 
      indications for RFB use were RMP-related AE (57%), con- current antiretroviral 
      therapy (21%), potential/actual interaction with other medications (14%), and as 
      part of an alternative regimen in liver disease (8%). Nineteen patients 
      experienced an AE while taking RFB. Among patients with a prior RMP-related AE, 
      80% of whom were successfully treated with RFB, only a dermatologic AE was 
      associated with subsequent RFB intolerance. CONCLUSIONS: Our study suggests that 
      RFB is well tolerated by patients who develop RMP-related AEs. There may be an 
      increased risk for RFB-related AE in patients who experienced RMP-related 
      dermatologic events.
FAU - Horne, D J
AU  - Horne DJ
AD  - Division of Pulmonary and Critical Care Medicine, University of Washington School 
      of Medicine, Seattle, Washington 98104, USA. dhorne@u.washington.edu
FAU - Spitters, C
AU  - Spitters C
FAU - Narita, M
AU  - Narita M
LA  - eng
GR  - K23 AI085036/AI/NIAID NIH HHS/United States
GR  - K23 AI085036-02/AI/NIAID NIH HHS/United States
GR  - K23 AI 85036-01/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - France
TA  - Int J Tuberc Lung Dis
JT  - The international journal of tuberculosis and lung disease : the official journal 
      of the International Union against Tuberculosis and Lung Disease
JID - 9706389
RN  - 0 (Antibiotics, Antitubercular)
RN  - 1W306TDA6S (Rifabutin)
RN  - VJT6J7R4TR (Rifampin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antibiotics, Antitubercular/adverse effects/*therapeutic use
MH  - Chi-Square Distribution
MH  - Drug Substitution
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Mycobacterium tuberculosis/*drug effects/isolation & purification
MH  - Rifabutin/adverse effects/*therapeutic use
MH  - Rifampin/adverse effects/*therapeutic use
MH  - Risk Assessment
MH  - Risk Factors
MH  - Time Factors
MH  - Treatment Outcome
MH  - Tuberculosis/diagnosis/*drug therapy/microbiology
MH  - Washington
PMC - PMC3290133
MID - NIHMS355354
COIS- Funding/financial disclosures: The authors have reported that no potential 
      conflicts of interest exist with any companies/organizations whose products or 
      services may be discussed in the article.
EDAT- 2011/10/20 06:00
MHDA- 2012/02/11 06:00
PMCR- 2012/02/29
CRDT- 2011/10/20 06:00
PHST- 2011/10/20 06:00 [entrez]
PHST- 2011/10/20 06:00 [pubmed]
PHST- 2012/02/11 06:00 [medline]
PHST- 2012/02/29 00:00 [pmc-release]
AID - 10.5588/ijtld.11.0068 [doi]
PST - ppublish
SO  - Int J Tuberc Lung Dis. 2011 Nov;15(11):1485-9, i. doi: 10.5588/ijtld.11.0068.